熱門資訊> 正文

Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042

2025-09-08 19:10

Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042.
Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。